BridgeBio Pharma Inc
Research BridgeBio Pharma Inc (BBIO) on Bullrun: market cap USD 12.76B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBBIO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 12.76B
- Financial periodQ2 2026
- RevenueUSD 243.68M
- Net income-USD 152.22M
- Free cash flow-USD 71.54M
- Gross margin93.8%
Valuation Snapshot
latest market cap is USD 12.76B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 502.08M | -USD 732.94M | -USD 447.01M | 95.8% | -3.78 | USD 570.12M | USD 2.01B | -USD 2.09B |
| FY2024 | USD 221.90M | -USD 543.35M | -USD 521.66M | 98.3% | -2.88 | USD 681.10M | USD 437.34M | -USD 1.47B |
| FY2023 | USD 9.30M | -USD 653.25M | -USD 529.03M | 73.7% | -3.95 | USD 375.94M | USD 446.45M | -USD 1.35B |
| FY2022 | USD 77.65M | -USD 484.63M | -USD 424.32M | 95.6% | -3.26 | USD 376.69M | USD 430.99M | -USD 1.25B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 12.76B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 14.90B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 5.21B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 7.02B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.14B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 2.46B | n/a | n/a | n/a |
About BridgeBio Pharma Inc
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name;
ETFs that hold BridgeBio Pharma Inc
BridgeBio Pharma Inc is one of the ten largest holdings of one ETF that investors in Europe can buy:
| ETF | Weight | TER |
|---|---|---|
| L&G Pharma Breakthrough UCITS ETF | 3.09% | 0.49% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BridgeBio Pharma Inc's market cap?
BridgeBio Pharma Inc's market capitalization is USD 12.76B.
What does BridgeBio Pharma Inc do?
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases.